Horizon Pharma plc, of Dublin, closed an underwritten public offering of about 17.7 million shares priced at $28.25 each. Including a full exercise by the underwriters of their option to purchase up to 2.3 million additional ordinary shares, Horizon raised about $475.2 million in net proceeds.